Literature DB >> 10694374

Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.

N Akeno1, A Matsunuma, T Maeda, T Kawane, N Horiuchi.   

Abstract

We investigated the effects of dexamethasone on vitamin D-1alpha-hydroxylase and -24-hydroxylase expression and on vitamin D receptor (VDR) content in the kidneys of mice fed either a normal (NCD) diet or a calcium- and vitamin D-deficient (LCD) diet for 2 weeks. For the last 5 days mice received either vehicle or dexamethasone (2 mg/kg per day s.c.). Dexamethasone significantly increased plasma calcium concentrations without changing plasma concentrations of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) in both NCD and LCD groups. Northern blot and enzyme activity analyses in NCD mice revealed that dexamethasone increased renal VDR mRNA expression modestly and greatly increased 24-hydroxylase mRNA abundance and enzyme activity, but did not affect 1alpha-hydroxylase mRNA abundance and enzyme activity. In mice fed an LCD diet, dexamethasone increased renal VDR mRNA expression 1.5-fold, decreased 1alpha-hydroxylase mRNA abundance (52%) and activity (34%), and markedly increased 24-hydroxylase mRNA abundance (16-fold) and enzyme activity (9-fold). Dexamethasone treatment did not alter functional VDR number (B(max) 125-141 fmol/mg protein) or ligand affinity (K(d) 0.13-0.10 nM) in LCD mice. Subcutaneous injections of 1,25(OH)(2)D(3) (0.24 nmol/kg per day for 5 days) into NCD mice strongly increased renal 24-hydroxylase mRNA abundance and enzyme activity, while there was no effect of dexamethasone on renal 24-hydroxylase expression in these mice. This may be due to overwhelming induction of 24-hydroxylase by 1,25(OH)(2)D(3). These findings suggest that glucocorticoid-induced osteoporosis is caused by direct action of the steroids on bone, and the regulatory effect of glucocorticoids on renal 25-hydroxyvitamin D(3) metabolism may be less implicated in the initiation and progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694374     DOI: 10.1677/joe.0.1640339

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  24 in total

Review 1.  Osteoporosis after transplantation.

Authors:  Carolina A Moreira Kulak; Victoria Z Cochenski Borba; Jaime Kulak; Melani Ribeiro Custódio
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

2.  Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006.

Authors:  Amy L Skversky; Juhi Kumar; Matthew K Abramowitz; Frederick J Kaskel; Michal L Melamed
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 3.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

Review 4.  Vitamin D and the kidney.

Authors:  Rajiv Kumar; Peter J Tebben; James R Thompson
Journal:  Arch Biochem Biophys       Date:  2012-03-15       Impact factor: 4.013

Review 5.  Vitamin D in organ transplantation.

Authors:  E M Stein; E Shane
Journal:  Osteoporos Int       Date:  2011-01-05       Impact factor: 4.507

6.  Glucocorticoid regulation of the vitamin D receptor.

Authors:  Alejandro A Hidalgo; Donald L Trump; Candace S Johnson
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-14       Impact factor: 4.292

7.  1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.

Authors:  Galina Nesterova; May Christine Malicdan; Kaori Yasuda; Toshiyuki Sakaki; Thierry Vilboux; Carla Ciccone; Ronald Horst; Yan Huang; Gretchen Golas; Wendy Introne; Marjan Huizing; David Adams; Cornelius F Boerkoel; Michael T Collins; William A Gahl
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

8.  Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach.

Authors:  Sihem Benaboud; Saïk Urien; Eric Thervet; Dominique Prié; Christophe Legendre; Jean-Claude Souberbielle; Déborah Hirt; Gérard Friedlander; Jean Marc Treluyer; Marie Courbebaisse
Journal:  Eur J Clin Pharmacol       Date:  2012-08-31       Impact factor: 2.953

Review 9.  Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.

Authors:  R N J de Nijs; J W G Jacobs; A Algra; W F Lems; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2004-05-07       Impact factor: 4.507

Review 10.  Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.

Authors:  Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino
Journal:  J Nephrol       Date:  2016-04-09       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.